The Histamine and Multiple Sclerosis Alliance: Pleiotropic Actions and Functional Validation.

Area of Science:

• Neuroimmunology
• Demyelinating Diseases
• Pharmacology

Background:

• Multiple sclerosis (MS) is characterized by neuroinflammation, demyelination, and neurodegeneration, with unclear etiology involving genetic and environmental factors.
• Current treatments for MS offer palliative care, highlighting the need for novel therapeutic strategies.
• Emerging evidence points to the involvement of histamine signaling in nervous system functions and pathologies, including MS.

Purpose of the Study:

• To present evidence supporting the link between histamine and multiple sclerosis (MS).
• To introduce innovative therapeutic strategies targeting histamine pathways for MS treatment.
• To explore the potential of histamine as an immunomodulatory and neuroprotective agent in MS.

Main Methods:

• Review of existing literature on histamine's role in neuroinflammation and demyelination.
• Analysis of studies investigating histamine levels in cerebrospinal fluid of MS patients.
• Exploration of preclinical and clinical data on histamine-based therapeutic interventions for MS.

Main Results:

• Histamine influences oligodendrocyte precursor differentiation, crucial for remyelination.
• Histamine can inhibit the adhesion of myelin-autoreactive T cells to brain vasculature, a key step in MS pathogenesis.
• Elevated histamine levels are observed in the cerebrospinal fluid of individuals with MS.

Conclusions:

• Histamine exhibits multifaceted roles in MS, impacting both disease progression and potential repair mechanisms.
• Histamine signaling represents a promising therapeutic target for developing novel treatments for multiple sclerosis.
• Further research into histamine's immunomodulatory and neuroprotective functions may unlock new paradigms for MS management.